1-9 of 9
in vivo exposure
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Karen W.L. Yee, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Elizabeth A. Griffiths, MD, Raoul Tibes, MD PhD, Katherine J. Walsh, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Elias Jabbour, MD, Todd L. Rosenblat, MD MS, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3846.
https://doi.org/10.1182/blood-2019-129845
Published: 2019
Journal Articles

Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles

Gail J. Roboz, MD, Hartmut Döhner, MD, Marco Gobbi, MD, Patricia L. Kropf, MD, Jiri Mayer, MD, Jürgen Krauter, MD, Tadeusz Robak, MD, Hagop M. Kantarjian, MD, Jan Novak, MD PhD, Wieslaw Jedrzejczak, MD, Xavier Thomas, MD PhD, Mario Ojeda-Uribe, MD, Yasushi Miyazaki, MD PhD, Yoo Hong Min, MD PhD, Su-Peng Yeh, MD, Joseph M Brandwein, MD, Liana Gercheva, MD, Judit Demeter, MD, Elizabeth A. Griffiths, MD, Karen W.L. Yee, MD, Jean-Pierre Issa, MD, Yong Hao, MD PhD, Mohammad Azab, MD, Pierre Fenaux, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2591.
https://doi.org/10.1182/blood-2019-127253
Published: 2019
Journal Articles

Progression Free Survival (PFS), and Event Free Survival (EFS) from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC): ASTRAL-1 Study

Jean-Pierre Issa, MD, Marco Gobbi, MD, Patricia L. Kropf, MD, Pierre Fenaux, MD PhD, Gail J. Roboz, MD, Jiri Mayer, MD, Jürgen Krauter, MD, Tadeusz Robak, MD, Hagop M. Kantarjian, MD, Jan Novak, MD PhD, Wieslaw W. Jedrzejczak, MD PhD, Xavier Thomas, MD PhD, Mario Ojeda-Uribe, MD, Yasushi Miyazaki, MD PhD, Yoo Hong Min, MD PhD, Su-Peng Yeh, MD, Joseph M Brandwein, MD, Liana Gercheva, MD, Judit Demeter, MD, Elizabeth A. Griffiths, MD, Karen W.L. Yee, MD, Yong Hao, MD PhD, Mohammad Azab, MD, Hartmut Döhner, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4235.
https://doi.org/10.1182/blood-2019-129614
Published: 2019
Journal Articles

Predictors of Response and Survival in 206 AML Patients Treated with Guadecitabine in a Phase 2 Study

Hagop M. Kantarjian, MD, Gail J. Roboz, MD, Patricia L Kropf, MD, Elias J. Jabbour, MD, Karen W.L. Yee, MD, Casey L. O'Connell, MD, Guillermo Garcia-Manero, MD, Elizabeth A. Griffiths, MD, Katherine J. Walsh, MD, Wendy Stock, MD, Raoul Tibes, MD PhD, Nikolai A. Podoltsev, MD PhD, Yong Hao, Valerie Ahanonu, Mohammad Azab, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3854.
https://doi.org/10.1182/blood.V130.Suppl_1.3854.3854
Published: 2017
Journal Articles

Multivariate Analysis Identifies Significant Correlations Between Baseline Biomarkers, DNA Demethylation and Clinical Responses in 122 Patients Treated in a Phase 1/2, Study of Guadecitabine (SGI-110), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (r/r AML)

Srikanth Gottipati, PhD, Shashank Rohatagi, PhD, Woonbok Chung, PhD, Pietro Taverna, PhD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD, Patricia L. Kropf, MD, Mohammad Azab, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2015) 126 (23): 2594.
https://doi.org/10.1182/blood.V126.23.2594.2594
Published: 2015
Journal Articles

Disregulated Osteogenesis By Mesenchymal Stromal Cells (MSC) After In Vivo Exposure To Multiple Myeloma: Studies In a Novel Humanized Mouse Model For Bone Remodelling In Myeloma

Richard W.J. Groen, PhD, Willy A. Noort, PhD, Jessica Sigmans, Aniek van Stralen, Linda Aalders, Reinier Raymakers, MD, PhD, Huipin Yuan, PhD, Constantine S. Mitsiades, MD, PhD, Anton Martens, PhD
Journal: Blood
Blood (2013) 122 (21): 1906.
https://doi.org/10.1182/blood.V122.21.1906.1906
Published: 2013
Journal Articles

A Novel View of Bone Marrow As a “stem Cell sensor” of Tissue/Organ Damage -Evidence That in Vivo Exposure to the Neurotoxin Kainic Acid (KA) Induces Proliferation and Neural Specification of Developmentally Early Stem Cells Directly in Bone Marrow Before They Are Mobilized Into Peripheral Blood

Katarzyna Grymula, PhD, Maciej Tarnowski, PhD, Malwina Suszynska, MS, Katarzyna Piotrowska, PhD, Sylwia Borkowska, MS, Kasia Mierzejewska, MS, Magdalena Kucia, Ph.D., Mariusz Z Ratajczak, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 1192.
https://doi.org/10.1182/blood.V120.21.1192.1192
Published: 2012
Journal Articles

Irradiated Bone Marrow Environment Impairs Hematopoietic Stem Cells by Exposure to Tumor Necrosis Factor a.

Sachie Suzuki, M.D., Motohito Okabe, Makoto Otsu, M.D., Ph.D., Hideo Ema, MD, PhD, Hiromitsu Nakauchi, M.D., Ph.D.
Journal: Blood
Blood (2010) 116 (21): 3724.
https://doi.org/10.1182/blood.V116.21.3724.3724
Published: 2010
Journal Articles

Mechanisms Responsible for and Strategies To Overcome Bone Marrow (BM) Rejection in Allosensitized Recipients.

Patricia A. Taylor, Michael J. Ehrhardt, Matthew M. Roforth, Jessica M. Swedin, Angela Panoskaltsis-Mortari, Jonathan S. Serody, Bruce R. Blazar
Journal: Blood
Blood (2006) 108 (11): 3212.
https://doi.org/10.1182/blood.V108.11.3212.3212
Published: 2006